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Abstract: OBJECTIVES Characteristics of Swiss patients with systemic sclerosis have not been de-
scribed so far. The aim of the current study was to identify unmet needs in comparison with other
European countries that could inform specific interventions to improve the care of systemic sclerosis
patients. METHODS We analysed Swiss and other European systemic sclerosis patients registered in
European Scleroderma Trials And Research (EUSTAR) and the Very Early Diagnosis Of Systemic Scle-
rosis (VEDOSS) cohort. Demographics, clinical profiles, organ involvement and survival of established,
early/mild and very early / very mild systemic sclerosis patients were described and compared between
the cohorts. RESULTS We included 679 Swiss and 8793 European systemic sclerosis patients in the
analysis. Over 95% of patients in both cohorts were Caucasian, disease subsets were similar, and no age
difference was found. The Swiss cohort had more male patients (25% vs 16% European, p = 0.005) and
higher prevalence of early/mild and very early / very mild patients (26.1 vs 8.5% European and 14.9% vs
6.7% European, respectively, both p lt;0.0001). Disease duration in established systemic sclerosis patients
at first presentation was numerically shorter but not significant in the Swiss cohort: 5.0 years (1ndash;12)
Swiss vs 6.0 years (2ndash;12) years European, p = 0.055). Despite the earlier referral of Swiss patients to
systemic sclerosis expert centres, they showed evidence of more severe disease, particularly in the limited
cutaneous systemic sclerosis subset, but no differences in overall survival on longitudinal follow-up were
observed. CONCLUSION This is the first report of the national Swiss EUSTAR cohort. It identifies
earlier referral to systemic sclerosis expert centres, before major organ damage occurs, and when outcome
can still be modified, as a priority to improve care of patients with systemic sclerosis.
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Summary
OBJECTIVES: Characteristics of Swiss patients with sys-
temic sclerosis have not been described so far. The aim of
the current study was to identify unmet needs in compar-
ison with other European countries that could inform spe-
cific interventions to improve the care of systemic sclero-
sis patients.
METHODS: We analysed Swiss and other European sys-
temic sclerosis patients registered in European Scleroder-
ma Trials And Research (EUSTAR) and the Very Early
Diagnosis Of Systemic Sclerosis (VEDOSS) cohort. De-
mographics, clinical profiles, organ involvement and sur-
vival of established, early/mild and very early / very mild
systemic sclerosis patients were described and compared
between the cohorts.
RESULTS: We included 679 Swiss and 8793 European
systemic sclerosis patients in the analysis. Over 95% of
patients in both cohorts were Caucasian, disease subsets
were similar, and no age difference was found. The Swiss
cohort had more male patients (25% vs 16% European, p
= 0.005) and higher prevalence of early/mild and very ear-
ly / very mild patients (26.1 vs 8.5% European and 14.9%
vs 6.7% European, respectively, both p <0.0001). Dis-
ease duration in established systemic sclerosis patients at
first presentation was numerically shorter but not signifi-
cant in the Swiss cohort: 5.0 years (1–12) Swiss vs 6.0
years (2–12) years European, p = 0.055). Despite the ear-
lier referral of Swiss patients to systemic sclerosis expert
centres, they showed evidence of more severe disease,
particularly in the limited cutaneous systemic sclerosis
subset, but no differences in overall survival on longitudi-
nal follow-up were observed.
CONCLUSION: This is the first report of the national Swiss
EUSTAR cohort. It identifies earlier referral to systemic
sclerosis expert centres, before major organ damage oc-
curs, and when outcome can still be modified, as a priority
to improve care of patients with systemic sclerosis.
Introduction
Systemic sclerosis (SSc) is a heterogeneous multisystem
autoimmune disorder, characterised by vasculopathy and
extensive tissue fibrosis with multiple organ involvement
[1, 2]. With estimates of prevalence from 3 to 50 per
100,000, SSc is an orphan disease, and is associated with
high morbidity and disease-related mortality [3, 4]. At pre-
sent, there is no licensed therapy that can prevent overall
disease progression [5].
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The aetiology of the disease is still unclear, but genetic and
environmental factors have been implicated [6]. There is a
higher susceptibility in females as well as in Afro-Amer-
icans, and geographical variations with higher prevalence
of SSc in the USA and Australia than in Japan and Europe
[7, 8]. Within Europe, a north-south gradient with high-
er prevalence in southern countries and higher prevalence
of more severe organ manifestations in eastern centres has
been described. However, differences between European
countries might be due to referral-and investigator-related
bias in the specific healthcare systems rather than true dif-
ferences in prevalence and severity [3, 6].
The American College of Rheumatology (ACR) classifi-
cation criteria from 1980 have been the most widely used
in epidemiological studies of SSc [3, 9]. However, as the
ACR criteria 1980 were developed for patients with long-
standing SSc, they show insufficient sensitivity for early/
mild and very early / very mild SSc patients [10–12]. The
lack of early diagnostic criteria and predictors of disease
progression are important limiting factors for identifica-
tion and treatment in the early and very early stages of
the disease [13]. Especially as internal organ involvement
occurs early and is often subclinical, detection of disease
in the so-called “window of opportunity”, which refers
to the time between first manifestations to development
of irreversible organ damage, is of great interest [13–16].
In 2013, the new ACR / European Alliance of Associ-
ations for Rheumatology (EULAR) classification criteria
including immunological, vascular and fibrotic features of
the disease were published. These criteria were validated
as highly sensitive and specific for SSc, and allow inclu-
sion of more patients into clinical studies [17–19]. Further,
the European Scleroderma Trials and Research (EUSTAR)
group defined preliminary criteria for diagnosis of very
early SSc. These included puffy fingers, (SSc-specific) an-
tinuclear antibodies, and microvascular alterations detect-
ed by nailfold capillaroscopy in addition to Raynaud’s phe-
nomenon [20]. These criteria aim to identify patients with
a predisposition to develop SSc fulfilling the classification
criteria SSc [21, 22].
In Switzerland, a national strategy for the management of
rare diseases offering prospects of improved medical care
and government-funded support has been developed and
approved [23]. In this context, it is essential to have a
good understanding of the specific needs of SSc patients
in Switzerland. The EUSTAR database was formed in June
2004, and since then has prospectively followed SSc pa-
tients in most European countries. It provides a unique op-
portunity to assess Swiss and European SSc patients. Fur-
ther, a comparison of Swiss with European SSc patients
leads to a better understanding of the geographical epi-
demiology of SSc and to identification of specificities of
clinical manifestations of SSc patients. To date, no charac-
terisation of Swiss SSc patients has been published.
In this study, we aimed to address this unmet need. This
analysis could represent a valuable asset to set priorities in
the clinical management strategy of SSc and thus guide the
direction of medical efforts and resources towards the best
care of patients.
Patients and methods
For this observational study, all SSc patients from the EU-
STAR centres in Switzerland (Zurich, Basel, Geneva, Aa-
rau, Bern, Lausanne) and Europe (excluding Swiss centres,
all included centres are listed in supplementary table S1 in
appendix 2) with visits entered into the EUSTAR or the as-
sociated VEDOSS database (for patient with very early /
very mild SSc) between 01 January 2009 and 30 October
2017 (date of data export) were analysed cross-sectionally.
The first visit after 01 January 2009 was used to charac-
terise patients. This date was chosen because by then the
online documentation was introduced and more complex
clinical data, including detailed information on therapies,
were available. Collection of the data from the VEDOSS
cohort started in July 2010 with participation of all EU-
STAR centres including patients with a predisposition to
develop early SSc according to recently developed criteria
[20].
All patients agreed to participate in the EUSTAR/VE-
DOSS database by signing informed consent forms ap-
proved by the local ethics committees. Ethics approval has
been obtained from the local ethics committees by all par-
ticipating EUSTAR and VEDOSS centres and the corre-
sponding ethics committee in Zurich gave approval for our
study (KEK-BASEC-Nr. 2017-02102). The study was con-
ducted in accordance with the principles of the Declaration
of Helsinki, local laws and guidelines for Good Clinical
Practice.
The database covers demographic aspects, disease dura-
tion, organ involvement, and laboratory and therapy data,
which have been described in detail previously [7, 24]. For
the present analysis, patients were grouped into late/estab-
lished (patients fulfilling the ACR 1980 classification cri-
teria), early/mild (patients fulfilling only the ACR/EULAR
2013, but not the ACR 1980 classification criteria) and
very early / very mild patients (patients not fulfilling any of
the classification criteria, but with evidence for SSc based
on the VEDOSS criteria) [9, 17, 20]. Patients from non-
European centres and patients with missing information for
the classification criteria were excluded from the analysis.
First, a descriptive analysis from the Swiss cohort with
EUSTAR and VEDOSS patients including disease charac-
teristics, organ involvement, antibody profile and laborato-
ry parameters was performed. Skin fibrosis was assessed
by the modified Rodnan skin score [25]. Presence of organ
involvement was defined as follows: interstitial lung dis-
ease (by low‐dose high‐resolution computed tomography
[CT] and/or X-ray), kidney involvement (presence of renal
crisis), conduction blocks (by electrocardiography), heart
involvement on echocardiography (any of the following:
pericardial effusion, diastolic dysfunction or left ventricu-
lar ejection fraction <50%), and clinical diagnosis of joint
synovitis. The New York Heart Association (NYHA) func-
tional classification was used to determine cardiac insuffi-
ciency. Clinical experts in the respective EUSTAR centres
determined the presence of organ involvement or certain
SSc parameters based on EUSTAR definitions [26, 27].
In a second step, characteristics of the Swiss EUSTAR pa-
tients were compared with European EUSTAR patients.
Disease characteristics, organ involvement, antibody pro-
file and survival were compared between the Swiss and
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European cohort by the subgroups diffuse cutaneous (dc-
SSc) and limited cutaneous SSc (lcSSc), according to the
Le Roy criteria 1988 [28].
Statistical analysis
For this cross-sectional study and longitudinal survival
analysis, continuous variables were tested for normal dis-
tribution with the Kolmogorov-Smirnoff test, and mean
and standard deviation (SD) or median and interquartile
range (IQR) were calculated. Categorical variables were
presented as frequencies (percentages). Statistical evalu-
ation between two groups was performed using the chi-
square or Fisher’s exact test for categorical variables and
the t-test or Mann-Whitney U test as appropriate for con-
tinuous variables. To address multiple testing, a Bonferroni
correction (α/number of tests) was applied and only p-val-
ues ≤0.0011 (0.05/45) were considered statistically signifi-
cant and marked as p*-values. Vital status was obtained at
the latest follow up. Survival curves were computed with
Kaplan-Meier analysis and survival estimates were statis-
tically tested with the log-rank test. Statistical analysis was
performed in IBM SPSS Statistics v. 23 software.
Results
Study population
At the time of data export, the EUSTAR registry comprised
a total of 10,863 European SSc patients (EUSTAR: 529
Swiss / 8036 European; VEDOSS: 150 Swiss / 757 Eu-
ropean) with at least one available visit after 01 January
2009. Excluded were 383 patients with missing data for
classification criteria (EUSTAR: 7 Swiss / 192 European;
VEDOSS: 1 Swiss / 183 European) and 1008 Patients from
EUSTAR fulfilling neither the ACR 1980 classification
criteria nor ACR/EULAR 2013 (80 Swiss / 928 European).
Thus, the final number of patients included in the analysis
were 679 patients from Switzerland and 8793 patients from
other European countries.
Analysis of the Swiss cohort
Of 679 Swiss patients, we found 401 (59.1%) established,
177 (26.1%) early/mild and 101 (14.9%) very early / very
mild cases. Demographics and disease characteristics, or-
gan involvement and antibody status are summarised in
table 1 and table 2. There were 66% female patients among
the established group and 88% in the early/mild and very
early / very mild group. Age was similar in the established
and early/mild groups (56.81 ± 13.61 and 57.46 ± 14.72
years, respectively) and lower in very early / very mild pa-
tients (47.70 ± 14.75 years). Over 94% in all groups were
Caucasian and over 95% had Raynaud’s phenomenon. Age
at onset of Raynaud’s phenomenon was again similar be-
tween established and early/mild (46.76 ± 16.53 and 47.23
± 17.73 years, respectively) and lower for very early / very
mild patients (39.93 ± 16.55 years). Age at onset of first
non-Raynaud’s phenomenon symptom (disease onset) was
lower in established (47.81 ± 15.2 years) than in early/mild
patients (51.02 ± 16.4 years).
Figure 1: Disease characteristics and organ involvement Switzerland and Europe.Peripheral vasculopathy: digital ulcers ever; joint involve-
ment: any of joint contracture, joint synovitis or tendon friction rubs; muscular involvement: any of muscle weakness or muscle atrophy; GIT
(gastrointestinal tract) involvement: any of oesophageal (dysphagia, reflux), stomach or intestinal symptoms; ILD (interstitial lung disease):
lung fibrosis on x-ray or HRCT; PAH (pulmonary artery hypertension): PAPsys >40 mm Hg by echo; heart involvement: left ventricular ejection
fraction <45%; kidney involvement: renal crisis.
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Specific analysis of the subgroups revealed certain char-
acteristics: the very early / very mild patients showed typ-
ical early/mild disease features: abnormal nailfold capil-
laroscopy pattern in 58.4% patients, followed by presence
of SSc-specific anti-centromere antibodies (ACA) in
42.6%, oesophageal involvement in 27%, puffy fingers
(20.8%) and telangiectasia (13%). Presence of anti-Scl70
antibodies, anti-RNA polymerase antibodies (RNAP) III
and digital ulcers was very low (4.0%, 7.4% and 4.0%, re-
spectively). Creatine kinase and the inflammation markers
C-reactive protein and erythrocyte sedimentation rate were
elevated in a small number of the very early / very mild pa-
tients (9.1%, 7.0% and 5.3%, respectively).
In the early/mild group, an abnormal scleroderma pattern
on nailfold capillaroscopy was present in 80.3% of the pa-
tients, followed by ACA antibodies (73.7%), puffy fingers
(70.7%) and telangiectasia (50.9%), a typical feature of lc-
SSc [29]. As expected, organ involvement was more fre-
quent than in very early / very mild patients: oesophageal
involvement 50.0%, lung fibrosis 17.4%. Similarly, early/
mild patients had more cardiovascular, gastrointestinal and
vascular manifestations, as well as higher inflammation
markers (table 2).
As expected, in established SSc, organ manifestations be-
came even more frequent (table 2). Although the appear-
ance of organ manifestations increased with disease sever-
ity, features that characterise early/mild SSc, such as puffy
fingers and ACA, were less frequent in established pa-
tients. The number of males was more than two-fold higher
in established SSc in comparison with early/mild and very
early patients, consistent with previous studies in SSc
[30–36]. Dyspnoea NYHA II was similar in all groups, but
with more severe cases (NYHA III/IV) in established pa-
tients. As expected, lung involvement was highest in estab-
lished patients with 44.5% of the patients having intersti-
tial lung disease based on chest CT or X-ray.
Cardiovascular involvement with diastolic dysfunction and
palpitation occurred often in established (33.8% and
16.6%) as well as early/mild patients (33.1% and 14.4%).
Left ventricular ejection fraction (LVEF) <45% was rare in
established (0.9%) and absent in early/mild and very early
/ very mild patients.







Very early / very mild SSc‡
n/total (%)
Total patients 679 401/679 (59.1) 177/679 (26.1) 101/679 (14.9)
Age, mean ± SD – 56.81 ± 13.61 57.46 ± 14.72 47.70 ± 14.75
Sex –
– Male 100/401 (24.9) 17/177 (9.6) 10/101 (9.9)
– Female 301/401 (75.1) 160/177 (90.4) 91/101 (90.1)
Race 2.5 (17)
– Caucasian 372/392 (94.9) 167/170 (98.2) 96/100 (96.0)
– African-American / African 13/392 (3.3) 1/170 (0.6) 2/100 (2.0)
– Asian 4/392 (1.0) 0/170 0/170
– Other 3/392 (0.8) 2/170 (1.2) 2/100 (2.0)
Disease subset le Roy 0.4 (2)
– dcSSC 151/399 (37.8) 0 NA
– lcSSc 248/399 (62.2) 128/128 (100) NA
mRSS, median (IQR) 8.0 (4–14) 0.0 (0–2) 0.0 (0–0)
Raynaud’s phenomenon 0.4 (3) 378/399 (94.7) 177/177 (100) 99/100 (99.0)
Age at onset of first RP symptom, mean ± SD 11.9 (81) 46.76 ± 16.53 47.23 ± 17.73 39.93 ± 16.55
Age at onset of first non-RP symptom, mean ±
SD
7.9 (42) 47.81 ± 15.2 51.02 ± 16.14 NA
Disease duration (years) median (IQR) 8.3 (44) 5.0 (1–12) 3.0 (1–9.5) NA
Difference first RP to first non-RP symptom
(months), median (IQR)
41.3 (165) 5.0 (0–48) 24.0 (0–125) NA
Digital ulcers (ever) 0.9 (6) 176/395 (44.6) 22/177 (12.4) 4/101 (4.0)
Digital ulcers active 3.4 (23) 68/378 (18.0) 13/177 (7.3) 4/101 (4.0)
Puffy fingers (ever) 5.3 (36) 217/368 (59.0) 123/174 (70.7) 21/101 (20.8)
Pitting scars 40.1 (272) 68/139 (48.9) 19/167 (11.4) 2/101 (2.0)
Joint synovitis 0.4 (3) 55/398 (13.8) 27/177 (15.3) 15/101 (14.9)
Joint contractures 1.7 (9) 152/393 (38.7) 11/127 (8.2) NA
Muscle weakness 1.1 (6) 70/394 (17.8) 10/129 (7.8) NA
Muscle atrophy 1.3 (7) 46/393 (11.7) 1/129 (0.8) NA
Tendon friction rubs 1.9 (13) 48/391 (12.3) 7/174 (4.0) 1/101 (1.0)
Scleroderma pattern 25.3% (176) 200/229 (87.3) 139/173 (80.3) 59/101 (58.4)
Scleroderma pattern if present 8.4 (25) NA
– Early pattern 42/181 (23.2) 34/90 (37.8) NA
– Active pattern 60/181 (44.2) 45/90 (50.0) NA
– Late pattern 59/181 (32.6) 11/90 (12.2) NA
Telangiectasia 39.5 (268) 86/143 (60.1) 85/167 (50.9) 13/101 (12.9)
dcSSc = diffuse cutaneous systemic sclerosis; IQR = interquartile range; lcSSc = limited cutaneous systemic sclerosis; mRSS = modified Rodnan skin score; NA = data not
available for VEDOSS patients; RP = Raynaud’s phenomenon; SD = standard deviation; SSc = systemic sclerosis * established SSc patients – ACR 1980 criteria positive; † early/
mild – ACR 1980 criteria negative and ACREULAR 2013 criteria positive; ‡ very early / very mild patients for both ACR 1980 and ACR/EULAR 2013 criteria negative
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Gastrointestinal symptoms were very common in all
groups and oesophageal symptoms were most often report-
ed. Renal crisis was rare and only present in established
patients. ANA (anti-nuclear antibodies) were found in all
groups, in from 93–98%. Similarly, joint synovitis had a
stable distribution among the groups, as did creatine kinase
elevation.
Comparison of Swiss and European patients
Demographic information of all included Swiss and other
European patients are listed in table 3. There was no dif-
ference found in age (55.7 ± 14.5 years Swiss / 55.4 ±
14.2 years European), and over 95% in both cohorts were
Caucasian. There were more male patients in Switzerland
(25% vs 16% European, p = 0.005). A significant dif-
ference in disease classification was found, with a higher
prevalence of established patients in other European coun-
tries (84.7% vs 59.1% Swiss, p <0.0001) and consequently
higher prevalence of early/mild (26.1% vs 8.5% European,
p <0.0001) and very early / very mild patients (14.9% vs
6.7% European, p <0.0001) in Switzerland. Disease sub-
sets according to Le Roy were similar: dcSSc 37.8% Swiss
/ 35.4% European and lcSSc 62.2% Swiss / 64.6% Euro-
pean [28].
Univariable comparison of Swiss and European estab-
lished patients summarised in figures 1 and 2 revealed no
major differences after correction for disease subsets. (De-
tails in supplementary tables S2 and S3 in appendix 2.)
Consistent differences were found for disease duration,
which was significantly shorter in established Swiss pa-
tients: 5.0 years (1–12) vs 7.0 years (3–13) European, p*
<0.0001). However, as only visits after 2009 were includ-
ed in this analysis, this difference might be caused by a
higher recruitment of patients into the database after 2009
in Switzerland without true differences in disease dura-
tion. To correct for this potential bias, we performed a sub-
analysis including only patients who had their first visit af-
ter 2009. In this subanalysis (82.1% of Swiss established
SSc patients and 62.4% of European established SSc pa-







Very early / very mild SSc‡
n/total (%)
Total patients 401/679 (59.1) 177/679 (26.1) 101/679 (14.9)
Lung
Dyspnoea 14.6 (99) 44/310 (14.2) 19/169 (11.2) 14/101 (13.9)
NYHA 15.2 (103)
– Stage I 156/313 (49.8) 105/168 (62.5) 82/95 (86.3)
– Stage II 113/313 (36.1) 55/168 (32.7) 13/95 (13.7)
– Stage III 38/313 (12.1) 7/168 (4.2) 0/95
– Stage IV 6/313 (1.9) 1/168 (0.6) 0/95
PH by echocardiography 9.0 (61) 64/351 (18.2) 12/169 (7.1) 1/98 (1.0)
PAPsys by echocardiography >40 mmg Hg 34.2 (232) 30/255 (11.8) 8/122 (6.6) 0/70
Lung fibrosis: HRCT or X-ray 12.4 (84) 153/344 (44.5) 28/161 (17.4) 2/90 (2.2)
FVC <80% predicted 11.6 (79) 80/341 (23.5) 13/168 (7.7) 8/91 (8.8)
DLCO <70 11.5 (78) 167/346 (48.3) 46/165 (27.9) 10/90 (11.1)
Cardiovascular
Arterial hypertension (BP >130/80 mm Hg) 3.2 (22) 108/398 (27.1) 42/170 (24.7) 19/89 (21.3)
Palpitation 2.3 (12) 65/392 (16.6) 18/125 (14.4) NA
Conduction blocks 20.9 (142) 39/294 (13.3) 13/147 (8.8) 9/96 (9.4)
LEVF <45% 12.8 (87) 3/339 (0.9) 0/162 0/91
Diastolic function abnormal 8.8 (80) 121/358 (33.8) 54/163 (33.1) 17/98 (17.3)
Pericardial effusion 12.1 (82) 31/344 (9.0) 3/159 (1.9) 0/94
Gastrointestinal
Oesophageal symptoms 0.4 (3) 252/399 (63.2) 88/176 (50.0) 28/101 (27.7)
Stomach symptoms 2.1 (11) 111/394 (28.2) 30/124 (24.2) NA
Intestinal symptoms 1.7 (9) 111/393 (28.2) 39/126 (31.0) NA
Renal crisis 0.3 (2) 14/399 (3.5) 0/171 0/101
Antibodies
ANA 1.2 (8) 383/393 (97.5) 174/177 (98.3) 94/101 (93.1)
ACA 4.6 (31) 133/372 (35.8) 129/175 (73.7) 43/101 (42.6
Anti-Scl70 2.7 (18) 139/389 (35.7) 23/171 (13.5) 4/101 (4.0)
Anti U1RNP 18.7 (127) 10/302 (3.3) 2/156 (1.3) 3/94 (3.2)
Anti RNA polymerase III 28.9 (196) 30/240 (12.5) 7/104 (6.7) 7/94 (7.4)
Laboratory data
CK elevation 5.9 (40) 47/370 (12.7) 17/170 (10.0) 9/99 (9.1)
Proteinuria 5.0 (34) 44/382 (11.5) 8/165 (4.8) 2/98 (2.0)
ESR >25 mm/h 11.5 (78) 88/335 (26.3) 29/166 (17.5) 5/95 (5.3)
CRP elevation 4.7 (32) 96/374 (25.7) 28/636 (16.2) 7/100 (7.0)
ACA = anti-centromere antibody; ANA = anti-nuclear antibody; BP = blood pressure; CK = creatine kinase; CRP = C-reactive protein; DLCO = diffusing capacity of the lung for
carbon monoxide; ESR = erythrocyte sedimentation rate; FVC = forced vital capacity; HRCT = High resolution computed tomography; LEVF = left ventricular ejection fraction;
NA = not available; NYHA = New York Heart Association; PAPsys = systolic pulmonary artery pressure; RNA = ribonucleic acid; Scl-70 = antitopoisomerase I antibody; SSc =
systemic sclerosis; U1RNP = uridine-rich ribonucleic protein * established SSc patients – ACR 1980 criteria positive; † early/mild – ACR 1980 criteria negative and ACREULAR
2013 criteria positive; ‡ very early / very mild patients for both ACR 1980 and ACR/EULAR 2013 criteria negative
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tients) there was still a shorter disease duration in the Swiss
patients, but without reaching statistical significance: 5.0
years (1–12) vs 6.0 years (2–12) European, p = 0.055).
Still, when looking at the whole cohort, disease duration
was shorter in Swiss patients across subgroups: in dcSSc
4.0 years (1–9) Swiss / 5.0 years (2–11) European, p =
0.003; in lcSSc 6.0 years (2–13) years Swiss / 8.0 (4–15)
years European, p = 0.015) and in Swiss early/mild pa-
Figure 2: Skin fibrosis in Switzerland and Europe. dcSSc = diffuse
cutaneous systemic sclerosis; lcSSc = limited cutaneous systemic
sclerosis; mRSS = modified Rodnan skin score
tients (3.0 (1–9) Swiss / 5.0 years (2–11) European, p =
0.016). However, it did not reach statistical significance af-
ter conservative correction for multiple testing using the
Bonferroni method (p-values ≤0.0011, marked as p*).
Despite the shorter disease duration, Swiss patients
showed overall evidence of a more severe disease, partic-
ularly in the lcSSc subset. In patients with lcSSc, signifi-
cantly higher percentage had tendon friction rubs (10.2%
Swiss / 3.9% European, p* <0.0001), and diastolic dys-
function (39.0% Swiss / 21.7% European, p* <0.0001).
Similarly, joint involvement (31.4% Swiss / 22.8% Eu-
ropean, p = 0.002), gastro-intestinal tract involvement
(76.6% Swiss / 67.7% European, p = 0.003) and renal cri-
sis (2.4% Swiss / 0.9% European, p = 0.037) were more
prevalent in Swiss lcSSc patients, but without reaching sta-
tistical significance after Bonferroni correction. In Swiss
dcSSc patients, significant differences were found only for
more prevalent RNA pol III antibodies (20.2% Swiss /
7.9% European, p* <0.0001). However, Swiss dcSSc pa-
tients did not show a milder disease than European dcSSc
patients, despite of their shorter disease duration (table S2).
Survival analysis
During the median follow up (duration from disease onset
to last visit / death) of 8.0 years (4–13) Swiss / 9.0 years
(4–14) European for dcSSc and 10 years (5–16) Swiss
/ 12.0 years (6–18) European for lcSSc patients, 13/151
(8.6%) Swiss / 250/2526 (9.5%) European dcSSc and 16/










Total Patients 679 8793
Age, mean ± SD - 55.70 ± 14.46 - 55.39 ± 14.22 p = 0.589
Sex - - p = 0.005
Male 127/679 (18.7) 1294/8793 (14.7)
Female 552/679 (81.3) 7499/8793 (85.3)
Race 2.5 (17) 13.5 (1190) p = 0.073
Caucasian 635/662 (95.9) 7375/7603 (97.0)
African-American/ African 16/662 (2.4) 96/7603 (1.3)
Asian 4/662 (0.6) 72/7603 (0.9)
Other 7/662 (1.1) 60/7603 (0.8)
Disease classification - -
Established 401/679 (59.1) 7451/8793 (84.7) p* <0.0001
Mild/early 177/679 (26.1) 751/8793 (8.5) p* <0.0001
Very early 101/679 (14.9) 591/8793 (6.7) p* <0.0001
Disease subset* 0.4 (2) 0.5 (39) p = 0.323
dcSSC 151/399 (37.8) 2625/7412 (35.4)
lcSSc 248/399 (62.2) 4787/7412 (64.6)
Age at onset of first RP symptom*,
mean ± SD
20.0 (80) 46.76 (16.53) 39.4 (2937) 44.13 (15.43) p = 0.003
dcSSC 47.14 ±14.94 44.01 ± 14.97 p = 0.028
lcSSc 46.72 ±17.39 44.19 ± 15.71 p = 0.030
Age at onset of first non-RP symp-
tom, mean ± SD
6.7 (27) 47.81 (15.2) 12.3 (917) 46.84 (14.49) p = 0.210
dcSSC 46.66 ± 14.29 44.98 ± 14.29 p = 0.175
lcSSc 48.56 ± 15.41 47.90 ± 14.56 p = 0.504
Disease duration, median (IQR)* 6.7 (27) 5.0 (1-12) 12.3 (917) 7.0 (3-13) p* <0.0001
dcSSC 4.0 (1–9) 5.0 (2–11) p = 0.003
lcSSc 6.0 (2–13) 8.0 (4–15) p = 0.015
Incident dcSSc 15.0 (10–23) 17.0 (9–25) p = 0.244
dcSSc = diffuse cutaneous systemic sclerosis; incident dcSSc = dcSSc patients with disease duration <3 years; IQR = interquartile range; lcSSc = limited cutaneous systemic
sclerosis; p* = p-value significant after Bonferroni correction (p-values ≤0.0011); RP = Raynaud's phenomen; SSc = systemic sclerosis; SD = standard deviation *comparison of
established SSc Patients only,
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248 (6.5%) Swiss / 295/4787 (6.1%) European lcSSc pa-
tients died. As illustrated in figures 3 and 4, there was no
significant difference of survival between Switzerland and
Europe in either dcSSc or lcSSc patients. The 10-year sur-
vival estimate (standard error) in dcSSc was 91.8% (3.2%)
Swiss / 93.1% (0.6%) European, and 15-year survival was
88.6% (4.5%) / 88.1% (1.0%), respectively. In lcSSc pa-
tients, 10-year survival was 92.2% (2.2%) Swiss / 97.1%
(0.3%) European and 15-year survival was 91.1% (2.5%) /
94.0% (0.5%), respectively.
Discussion
This is the first description of the Swiss EUSTAR cohort.
Our cross-sectional analysis provides a detailed overview
of the clinical profile of the Swiss SSc patients. Applica-
tion of ACR 1980 classification criteria, the ACR/EULAR
2013 classification criteria and inclusion of patients from
the VEDOSS database with very early / very mild and ear-
ly/mild disease allowed us to include a wide range of SSc
patients.
The current analysis showed that the Swiss EUSTAR/VE-
DOSS registry includes a larger part of the Swiss SSc
population. Considering that the published prevalence esti-
mates for Europe are 3 to 50 per 105 [3, 4], the Swiss EU-
STAR registry covers, with 8 per 105, a remarkable part
Figure 3: Kaplan-Meier survival analysis dcSSc patients. dcSSc =
diffuse cutaneous systemic sclerosis; RP = Raynaud’s phenome-
non.
Figure 4: Kaplan-Meier survival analysis lcSSc patients. lcSSc =
limited cutaneous systemic sclerosis; RP = Raynaud’s phenome-
non
of the expected number of patients in Switzerland [37]. In
general, prevalence numbers have to be interpreted with
caution because they strongly depend on the definition of
SSc and on the quality of the epidemiological data. In ad-
dition, prevalence data do not exist for Switzerland and are
thus estimated from other European countries. However,
even considering these limitations, the calculated 8 per 105
lies within the expected range and allows us to assume a
remarkable coverage of SSc patients in Switzerland. Still,
one has to realise that the EUSTAR Swiss cohort does not
cover all SSc patients, as registration is not mandatory. A
centre effect with registration of more severe patients into
the EUSTAR SSc expert centres can therefore not be ex-
cluded.
EUSTAR centres are requested to include all consecutive
patients into the registry to avoid selection biases. Indeed,
in the Swiss EUSTAR cohort, the frequencies of organ
manifestations for different subsets of the disease, as well
as other disease features, are very similar to those in other
databases [3, 6, 24]. Accordingly, comparison of Swiss and
European patients revealed no major differences after cor-
rection for disease subsets in the current analysis. These
data support the assumption that the Swiss EUSTAR co-
hort is a representative cohort for Swiss SSc patients and
can be used to further define specific national needs, to
monitor the use of certain treatments and treatment re-
sponses, document the natural course of the disease over
time and possibly even for socioeconomic estimates.
The only remarkable difference between the Swiss and Eu-
ropean EUSTAR SSc patients was the shorter disease du-
ration when first registered into the database. Even though
the difference did not remain statistically significant after
correction for potential confounding factors, a meaningful
difference of a 1-year shorter disease duration for Swiss
SSc patients remained. The most likely explanation for the
difference is that the highly developed Swiss healthcare
system allows early referral of patients with rare, orphan
diseases such as SSc to expert tertiary centres. Early refer-
ral is of high importance for the care of SSc patients, as
it provides a window of opportunity for early intervention
and risk stratification before irreversible organ damage oc-
curs. Delayed inclusion in the registry after the patient
was seen and inclusion of selected rather than consecu-
tive patients in other European SSc centres could also have
played a role.
Early intervention has been shown to improve long-term
outcome in other chronic inflammatory diseases [38].
However, despite their earlier referral, the Swiss EUSTAR
SSc patients did not show a better long-term outcome.
Survival was not significantly different in Swiss SSc pa-
tients compared with other European patients. Swiss pa-
tients with lcSSc even presented with evidence for more
severe disease compared with the SSc patients from other
European countries. Several possible explanations can be
considered:
1. SSc interstitial lung disease is the most frequent cause of
death in SSc [39]. Treatments have been implemented only
during very recent years, including a more frequent use of
mycophenolate mofetil and nintedanib, the first registered
targeted therapy for SSc interstitial lung disease [40–45].
These novel treatments possibly affect survival only in the
long term, which cannot be analysed when these changes
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in treatment occurred only recently. Longer-term follow up
and re-analyses in several years could address this hypoth-
esis.
2. With the exception of haematopoietic stem cell trans-
plantation [46], which is recommended only for a small
subgroup of patients with rapidly progressive SSc at high
risk of organ failure [47], treatments modifying the overall
disease course of SSc beyond single organ manifestations
are not available at present. This does not exclude benefi-
cial effects of early intervention with standard of care on
specific organ manifestations and patient well-being, but it
might not lead to an overall improvement in survival.
3. Most importantly, earlier referral as seen for the Swiss
SSc patients might not be early enough. Indeed, a recent
analysis of the EUSTAR database showed that patients
who were seen as early as within the first year after onset
of Raynaud’s phenomenon already had meaningful and
frequent organ involvement [48]. This is further supported
by data from the Norwegian national SSc cohort, which
showed that SSc interstitial lung disease is already fre-
quently detected at first presentation to the SSc centres,
and only a few patients develop interstitial lung disease at
follow up [49]. Thus, our and other data indicate that even
more efforts are needed to be made to identify patients with
SSc as early as possible, before meaningful organ damage
occurs, to ensure referral to an expert centre and to initiate
very early risk stratification and treatment.
Our study also has limitations: The EUSTAR registry is an
observational real-life database. As such, it has missing da-
ta, which limited some of the analysis. For example, be-
cause of missing data, the ACR/EULAR criteria could not
be calculated in 9.1% of EUSTAR patients, who then were
not included into the analysis. However, for all key SSc
characteristics, the EUSTAR database has a remarkably
low amount of missing data (tables 1 and 2). After all, the
EUSTAR database is run by mostly academic tertiary ex-
pert centres. There is no financial compensation for putting
patients into the registry, which makes it difficult for small-
er centres and private practices to contribute. Thus, while
the Swiss SSc EUSTAR cohort covered remarkably a high
percentage of the expected Swiss SSc patients, a recruit-
ment bias for more severe patients cared for in tertiary cen-
tres cannot be excluded.
Taken together, our study provides the first report on the
national Swiss EUSTAR cohort. Clinical profiles for dif-
ferent subforms of the disease were reported. We showed
that the recruited patients are representative for a typical
European SSc population, which emphasises the high bur-
den of disease for SSc patients in Switzerland. Compared
with other European centres, we could show an earlier re-
ferral of SSc patients. Despite this early referral, outcomes
were not different in the Swiss SSc patients. This indicates
that more efforts need to be made to allow referral of SSc
patients at risk even before severe organ damage has oc-
curred.
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Appendix: Supplementary tables
Table S1: List of all included European centres.
Countries (number of centres) Centres (centre number)
Belgium (3) Brussels (122), Gent (113), Leuven (126)
Croatia (5) Osijek (181), Rijeka (024), Split (041), Zagreb (051,128)
Czech Republic (2) Prague (007, 020)
Denmark (2) Copenhagen (116), Hellerup (086)
Estonia (1) Tallin (130)
France (11) Grenoble (170), Paris (017, 035, 112, 171), Lile (093), Marseille (134), Strasbourg (172,189), Toulouse (211),
Valence (138)
Germany (17) Bad Bramstedt (187), Bad Nauheim (081), Berlin (015), Bon (060), Dresden (125), Erlangen (106), Frankfurt
(124), Frankfurt am Main (063), Hamburg (064, 209), Köln (044), Lübeck (199), Münster (102), Munich (119),
Stuttgart (058), Tübingen (056), Wuppertal (192)
Greece (2) Athens (018, 213)
Hungary(2) Debrecen (087), Pecs (025)
Italy (27) Ancona (034),Bari (004), Bergamo (182), Brescia (038), Cagania (161), Florence (001), Foggia (115), Geno-
va (011, 085), Ferrera (043), Milano (074, 083, 110, 205, 212), Monserrato (CA) (142), Monza (118), Napoli
(013,210), Padova (031), Pavia(019),Reggio Emilia (066), Roma (094, 158, 186), Torino (049), Verona (050)
Ireland (1) Dublin (149)
Lithuania (2) Kaunas (140), Vilnius (176)
Malta (1) Blaza (033)
Moldova (1) Chisinau (137)
Norway(1) Oslo (092)
Poland (9) Bialystock (008), Cracow (157), Gdansk (194), Katowice (029), Lublin (059), Poznan (193), Szczecin (206),
Warsaw (166), Wroclaw (120)
Portugal (4) Bissaia Barreto (200), Coimbra (068), Lisboa (198), Viseu (184)
Romania (6) Bucharest (096, 100, 160), Cluj-Napoca (016), Iasi (162, 202)
Russa (2) Moscow (078, 190)
Serbia and Montenegro (2) Belgrade (055), Niska Banja (073)
Slovenia (1) Ljublijana (032)
Spain (6) Barcelona (057, 180), Madrid (023, 169, 196), Valencia (123)
Sweden (1) Lund (040)
Turkey (4) Bornova Izmir (159), Edirne (203); Istanbul (021,133)
United Kingdom (4) Leeds (175), London (052), Middlesbrough (165), Salford (080)
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Total patients 401/679 (59.1) 7451/8793 (84.7)
Le Roy disease subset 0.4 (2) 0.5 (39) p = 0.323
– dcSSC 151/399 (37.8) 2625/7412 (35.4)
– lcSSc 248/399 (62.2) 4787/7412 (64.6)
Age, mean ± SD - -
– dcSSC 53.82 ± 12.59 52.49 ± 13.48 p = 0.237
– lcSSc 58.56 ± 13.9 57.96 ± 13.53 p = 0.499
Sex
– dcSSC - - p = 0.003
Male 52/151 (34.4) 624/2625 (23.8)
Female 99/151 (65.6) 2001/2625 (76.2)
– lcSSc - - p* <0.0001
Male 48/248 (19.4) 519/4787 (10.8)
Female 200/248 (80.6) 4268/4787 (89.2)
Raynaud’s
– dcSSC - 142/151 (94.0) 1.0 (25) 2530/2600 (97.3) p = 0.038
– lcSSc 0.8 (2) 235/246 (95.5) 1.4 (68) 4599/4719 (97.5)
mRSS, median (IQR)
– dcSSC 4.6 (7) 14.0 (10–22) 12.4 (325) 14.0 (8–21) p = 0.312
– lcSSc 3.2 (8) 5.0 (2-9) 15.1 (721) 5.0 (2-8) p = 0.240
Digital ulcers(ever)
– dcSSC 1.3 (2) 70/149 (47.0) 3.3 (87) 1217/2538 (48.0) p = 0.818
– lcSSc 1.6 (4) 73/241 (30.3) 4.7 (226) 1576/4561 (34.6) p = 0.141
Joint synovitis
– dcSSC 0.7 (1) 22/150 (14.7) 3.2 (84) 447/2541 (17.6) p = 0.359
– lcSSc 0.8 (2) 32/246 (13.0) 4.2 (200) 552/4587 (12.0) p = 0.648
Joint contractures
– dcSSC 2.6 (4) 75/147 (51.0) 3.7 (96) 1160/2529 (45.9) p = 0.223
– lcSSc 1.2 (3) 77/245 (31.4) 4.5 (216) 1041/4571 (22.8) p = 0.002
Tendon friction rubs
– dcSSC 4.0 (6) 23/145 (15.9) 4.7 (124) 337/2501 (13.5) p = 0.415
– lcSSc 1.6 (4) 25/244 (10.2) 5.1 (244) 175/4543 (3.9) p*<0.0001
Muscle weakness
– dcSSC 1.3 (2) 35/149 (23.5) 3.7 (96) 677/2529 (26.8) p = 0.379
– lcSSc 1.6 (4) 35/244 (14.3) 4.9 (235) 651/4552 (14.3) p = 0.985
Muscle atrophy
– dcSSC 2.6 (4) 25/147 (17.0) 4.0 (105) 368/2520 (14.6) p = 0.424
– lcSSc 1.2 (3) 21/245 (8.6) 5.2 (247) 259/4540 (5.7) p = 0.063
Telangiectasia
– dcSSC 67.5 (102) 29/49 (59.2) 66.6 (1748) 501/877 (57.1) p = 0.777
– lcSSc 62.9 (156) 57/92 (62.0) 71.2 (3409) 849/1378 (61.6) p = 0.947
Abnormal NFC
– dcSSC 46.4 (70) 72/81 (88.9) 56.4 (1480) 1046/1145 (91.4) p = 0.419
– lcSSc 40.7 (101) 128/147 (87.1) 27.5 (722) 1697/1903 (89.2) p = 0.412
dcSSc = diffuse cutaneous systemic sclerosis; IQR = interquartile range; lcSSc = limited cutaneous systemic sclerosis; NFC = nailfold capillaroscopy; RP = Raynaud’s phenome-
non; SD = standard deviation; SSc = systemic sclerosis; p* = p-value significant after Bonferroni correction (p-values ≤0.0011)
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Total patients 401/679 (59.1) 7451/8793 (84.7) p* <0.0001
Le Roy disease subset 0.4 (2) 0.5 (39) p = 0.323
– dcSSC 151/399 (37.8) 2625/7412 (35.4)
– lcSSc 248/399 (62.2) 4787/7412 (64.6)
Lung
Dyspnoea
– dcSSC 23.2 (35) 20/116 (17.2) 9.6 (252) 330/2373 (13.9) p = 0.313
– lcSSc 22.6 (56) 23/192 (12.0) 11.5 (550) 440/4237 (10.4) p = 0.480
PH by echocardiography
– dcSSC 9.9 (15) 22/136 (16.2) 17.9 (471) 359/2154 (16.7) p = 0.882
– lcSSc 13.7 (34) 42/214 (19.6) 18.8 (900) 648/3887 (16.7) p = 0.261
PAPsys >40 mmg Hg
– dcSSC 33.1 (50) 10/101 (9.9) 41.3 (1083) 202/1542 (13.1) p = 0.353
– lcSSc 38.3 (95) 20/153 (13.1) 38.5 (1844) 399/2943 (13.6) p = 0.864
Lung fibrosis on HRCT or chest X–ray
– dcSSC 9.3 (14) 79/137 (57.7) 10.8 (284) 1343/2341 (57.4) p = 0.946
– lcSSc 17.3 (43) 72/205 (35.1) 16.6 (795) 1451/3992 (36.3) p = 0.722
FVC <80% predicted
– dcSSC 13.9 (21) 48/130 (36.9) 24.5 (642) 742/1983 (37.4) p = 0.910
– lcSSc 15.3 (38) 32/210 (15.2) 22.8 (1091) 624/3696 (16.9) p = 0.535
DLCOsb <70
– dcSSC 12.6 (19) 77/132 (58.3) 23.9 (628) 1255/1997 (62.8) p = 0.300
– lcSSc 14.1 (35) 90/213 (42.3) 23.3 (1116) 1773/3671 (48.3) p = 0.860
Cardiovascular
Palpitation
– dcSSC 2.6 (4) 19/147 (12.9) 3.5 (92) 593/2533 (23.4) p = 0.003
– lcSSc 1.6 (4) 46/244 (18.9) 6.0 (287) 863/4500 (19.2) p = 0.900
Conduction blocks
– dcSSC 25.2 (38) 16/113 (14.2) 14.1 (371) 358/2254 (15.9) p = 0.624
– lcSSc 27.4 (68) 23/180 (12.8) 17.5 (836) 476/3951 (12.0) p = 0.769
Left ventricular ejection fraction < 45
– dcSSC 13.9 (21) 1/130 (0.8) 30.4 (797) 53/1828 (2.9) p = 0.152
– lcSSc 16.1 (40) 2/208 (1.0) 30.7 (1470) 53/3317 (1.6) p = 0.770
Diastolic function abnormal
– dcSSC 7.9 (12) 36/139 (25.9) 20.3 (533) 487/2092 (23.3) p = 0.480
– lcSSc 12.1 (30) 85/218 (39.0) 21.9 (1050) 810/3737 (21.7) p* <0.0001
Pericardial effusion
– dcSSC 11.9 (18) 12/133 (9.0) 26.5 (695) 156/1930 (8.1) p = 0.702
– lcSSc 15.3 (38) 19/210 (9.0) 27.1 (1296) 220/3491 (6.3) p = 0.116
Gastrointestinal
Oesophageal symptoms
– dcSSC 0.7 (1) 90/150 (60.0) 0.8 (22) 1719/2603 (66.0) p = 0.130
– lcSSc 0.4 (1) 160/247 (64.8) 1.1 (52) 2804/4735 (59.2) p = 0.083
Stomach symptoms
– dcSSC 1.3 (2) 47/149 (31.5) 2.5 (66) 662/2559 (25.9) p = 0.126
– lcSSc 1.6 (4) 63/244 (25.8) 4.2 (202) 847/4585 (18.5) p = 0.004
Intestinal symptoms
– dcSSC 1.3 (2) 38/149 (25.5) 2.2 (58) 644/2567 (25.1) p = 0.909
– lcSSc 1.6 (4) 73/244 (29.9) 4.1 (194) 1063/4593 (23.1) p = 0.015
Renal crisis
– dcSSC 0.7 (1) 8/150 (5.3) 2.2 (58) 77/2567 (3.0) p = 0.111
– lcSSc 0.4 (1) 6/247 (2.4) 3.9 (188) 43/4599 (0.9) p = 0.037
Antibody status
ANA
– dcSSC - 144/151 (95.4) 5.1 (134) 2368/2491 (95.1) p = 0.868
– lcSSc 2.8 (7) 238/241 (98.8) 6.6 (316) 4277/4471 (95.7) p = 0.019
ACA
– dcSSC 7.9 (12) 13/139 (9.4) 10.5 (276) 206/2349 (8.8) p = 0.814
– lcSSc 6.5 (16) 120/232 (51.7) 10.4 (496) 2166/4291 (50.5) p = 0.711
Anti–Scl70
– dcSSC 1.3 (2) 82/149 (55.0) 8.0 (209) 1520/2416 (62.9) p = 0.054
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– lcSSc 3.6 (9) 57/239 (23.8) 10.8 (515) 945/4272 (22.1) p = 0.532
Anti U1RNP
– dcSSC 20.5 (31) 2/120 (1.7) 30.8 (809) 68/1816 (3.7) p = 0.238
– lcSSc 27.0 (67) 8/181 (4.4) 30.1 (1443) 146/3344 (4.4) p = 0.972
Anti RNA polymerase III
– dcSSC 34.4 (52) 20/99 (20.2) 47.6 (1250 108/1375 (7.9) p* <0.0001
– lcSSc 43.1 (107) 10/141 (7.1) 45.3 (2167) 66/2620 (2.5) p = 0.005
ACA = anti-centromere antibody; ANA = anti-nuclear antibody; dcSSc = diffuse cutaneous systemic sclerosis; DLCO = diffusing capacity of the lung for carbon monoxide; FVC
= forced vital capacity; HRCT = High resolution computer tomography; lcSSc = limited cutaneous systemic sclerosis; LEVF = left ventricular ejection fraction; PAPsys = systolic
pulmonary artery pressure; PH = pulmonary hypertension; RNA = ribonucleic acid; Scl-70 = anti-topoisomerase I antibody; SSc = systemic sclerosis; U1RNP = uridine-rich ri-
bonucleic protein; p* = p-value significant after Bonferroni correction (p-values ≤0.0011)
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